Understanding Your Diagnosis: Thomsen and Becker Disease
At a Glance
Thomsen and Becker disease are inherited forms of myotonia congenita caused by CLCN1 changes that delay muscle relaxation. Thomsen is usually dominant and milder, while Becker is recessive and often more severe, but symptoms can overlap and treatment can reduce stiffness.
Learning you have myotonia congenita—whether it was called Thomsen or Becker disease—can be overwhelming, but understanding the biology of the condition is often the first step toward managing it effectively. This is a rare muscle disorder where the primary issue is that your muscles have trouble relaxing after you use them [1].
Unlike more well-known muscle diseases, myotonia congenita is a channelopathy, a condition caused by a malfunction in the “gates” (channels) that control electrical signals in your muscle cells [1]. It is not a muscular dystrophy, meaning it does not typically cause your muscles to waste away over time or lead to systemic problems like cataracts or heart failure [2][3].
The Science of Muscle Relaxation
To understand your diagnosis, it helps to know how a healthy muscle works. Every time you move, your brain sends an electrical signal to your muscles. For a muscle to relax, it needs to reset its electrical charge. This “reset” is controlled largely by chloride channels, which act like brakes on a car, stopping the electrical activity so the muscle can rest [1][4].
In myotonia congenita, mutations in the CLCN1 gene cause these chloride channels to work improperly [1]. Without enough chloride “braking” the system, your muscle fibers remain electrically “excited” even after you try to stop moving [4]. This results in myotonia, the medical term for delayed muscle relaxation that feels like stiffness or cramping [5].
Thomsen vs. Becker: Understanding the Difference
Doctors traditionally divide myotonia congenita into two types based on how they are inherited and how they typically appear. However, modern research shows that these two types can often overlap, and the distinction is not always a perfect predictor of how an individual will feel. A neuromuscular geneticist will interpret your specific variants in context [6][7].
| Feature | Thomsen Disease | Becker Disease |
|---|---|---|
| Inheritance | Autosomal Dominant: Only one parent needs to pass on the gene [5]. | Autosomal Recessive: Both parents must carry the gene [5]. |
| Typical Onset | Often ages 4 to 20 [8]. | Often ages 2 to 15 [8]. |
| Severity | Generally considered milder [5]. | Often more severe; may involve transient weakness [5]. |
| Muscle Appearance | May appear normal. | Often involves hypertrophy (unusually large muscles) [5]. |
While Becker disease is often associated with transient weakness—a sudden, temporary loss of strength when you first try to move—this can also occur in Thomsen disease [9][6]. Genetic testing is the most reliable way to help determine which form you have, though clinical features also play a role [10].
Clarifying Common Misconceptions
It is important to distinguish myotonia congenita from myotonic dystrophy, as the names are similar but the conditions are very different:
- Targeted Impact: Myotonia congenita is almost exclusively a skeletal muscle disorder [2]. It does not cause the “wasting” seen in dystrophies, and patients often have a normal life expectancy [11].
- Systemic Issues: Unlike myotonic dystrophy, myotonia congenita does not typically cause cataracts, diabetes, or significant heart muscle disease [2][3]. While some rare reports mention heart rhythm issues, they are not a standard feature of the disease [12]. (However, any new symptoms like fainting or palpitations should still be evaluated by your doctor).
- The Warm-Up Phenomenon: A hallmark of this condition is that stiffness is often worst after rest but improves as you continue to move [13]. This “warm-up” allows many people to lead active lives once they get moving [13].
Managing Your Symptoms
Myotonia congenita is a manageable condition. While there is no cure for the underlying genetic mutation, several options exist to reduce muscle stiffness if it interferes with your life:
- Medications: Mexiletine is the most common first-line treatment for reducing stiffness [14][15]. If that is not tolerated, other options like lamotrigine may be used [16].
- Lifestyle Adjustments: Many patients find that regular, gentle exercise helps keep their muscles mobile [17]. It is also vital to inform any surgical team about your diagnosis, as certain types of anesthesia require special precautions for people with myotonia [18].
Understanding that your stiffness is a result of an electrical “reset” issue rather than muscle damage can help you and your care team focus on the most effective ways to keep you moving comfortably.
Common questions in this guide
What is the difference between Thomsen disease and Becker disease?
What does a CLCN1 mutation do in myotonia congenita?
How are Thomsen and Becker disease diagnosed?
Why does myotonia congenita improve after I start moving?
How is myotonia congenita different from myotonic dystrophy?
What treatments can reduce stiffness in Thomsen or Becker disease?
What should I tell my anesthesia team before surgery if I have myotonia congenita?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Types of the condition
Does my type, Thomsen or Becker, affect how the condition may feel day to day?
Genetic testing
Would genetic testing help tell whether I have Thomsen or Becker disease?
Weakness and stiffness
Can transient weakness occur with Thomsen disease too, or is it mainly Becker?
Get notified when new evidence is published on Thomsen and Becker disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Defective Gating and Proteostasis of Human ClC-1 Chloride Channel: Molecular Pathophysiology of Myotonia Congenita.
Jeng CJ, Fu SJ, You CY, et al.
Frontiers in neurology 2020; (11()):76 doi:10.3389/fneur.2020.00076.
PMID: 32117034 - 2
Myotonia: Recognition, Evaluation, and Differential Diagnosis.
Crayle JI, Al-Lozi M, Miller TM
Muscle & nerve 2026; (74(4)):1174-1195 doi:10.1002/mus.70250.
PMID: 42108746 - 3
Co-occurrence of DMPK expansion and CLCN1 mutation in a patient with myotonia.
Locci S, Cardani R, Brunori P, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):5365-5368 doi:10.1007/s10072-021-05538-y.
PMID: 34386887 - 4
Case report: Multiple approach analysis in a case of clinically assessed myotonia congenita.
Lucchiari S, Fortunato F, Meola G, et al.
Frontiers in genetics 2024; (15()):1486977 doi:10.3389/fgene.2024.1486977.
PMID: 39712484 - 5
Association of Three Different Mutations in the CLCN1 Gene Modulating the Phenotype in a Consanguineous Family with Myotonia Congenita.
Souza LS, Calyjur P, Ribeiro AF, et al.
Journal of molecular neuroscience : MN 2021; (71(11)):2275-2280 doi:10.1007/s12031-020-01785-4.
PMID: 33464536 - 6
Clinical and genetic characteristics of myotonia congenita in Chinese population.
He Y, Qiu Y, Xiong Y, et al.
Channels (Austin, Tex.) 2024; (18(1)):2349823 doi:10.1080/19336950.2024.2349823.
PMID: 38720415 - 7
Translating genetic and functional data into clinical practice: a series of 223 families with myotonia.
Suetterlin K, Matthews E, Sud R, et al.
Brain : a journal of neurology 2022; (145(2)):607-620 doi:10.1093/brain/awab344.
PMID: 34529042 - 8
CLCN1 Molecular Characterization in 19 South-Italian Patients With Dominant and Recessive Type of Myotonia Congenita.
Orsini C, Petillo R, D'Ambrosio P, et al.
Frontiers in neurology 2020; (11()):63 doi:10.3389/fneur.2020.00063.
PMID: 32117024 - 9
First Two Case Reports of Becker's Type Myotonia Congenita in Colombia: Clinical and Genetic Features.
Olave-Rodriguez JA, Bonilla-Escobar FJ, Candelo E, Rodriguez-Rojas LX
The application of clinical genetics 2021; (14()):473-479 doi:10.2147/TACG.S323559.
PMID: 34938096 - 10
Diagnostics in skeletal muscle channelopathies.
Vicino A, Brugnoni R, Maggi L
Expert review of molecular diagnostics 2023; (23(12)):1175-1193 doi:10.1080/14737159.2023.2288258.
PMID: 38009256 - 11
Clinical and molecular characteristics of myotonia congenita in China: Case series and a literature review.
Li Y, Li M, Wang Z, et al.
Channels (Austin, Tex.) 2022; (16(1)):35-46 doi:10.1080/19336950.2022.2041292.
PMID: 35170402 - 12
The Clinical, Myopathological, and Genetic Analysis of 20 Patients With Non-dystrophic Myotonia.
Wang Q, Zhao Z, Shen H, et al.
Frontiers in neurology 2022; (13()):830707 doi:10.3389/fneur.2022.830707.
PMID: 35350395 - 13
Case report: Sodium and chloride muscle channelopathy coexistence: A complicated phenotype and a challenging diagnosis.
Pagliarani S, Meola G, Filareti M, et al.
Frontiers in neurology 2022; (13()):845383 doi:10.3389/fneur.2022.845383.
PMID: 36081873 - 14
Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Vicart S, Franques J, Bouhour F, et al.
Neuromuscular disorders : NMD 2021; (31(11)):1124-1135 doi:10.1016/j.nmd.2021.06.010.
PMID: 34702654 - 15
Preclinical study of the antimyotonic efficacy of safinamide in the myotonic mouse model.
Canfora I, Altamura C, Desaphy JF, et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2024; (21(6)):e00455 doi:10.1016/j.neurot.2024.e00455.
PMID: 39322473 - 16
The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
Andersen G, Hedermann G, Witting N, et al.
Brain : a journal of neurology 2017; (140(9)):2295-2305 doi:10.1093/brain/awx192.
PMID: 29050397 - 17
Aerobic training in myotonia congenita: Effect on myotonia and fitness.
Andersen G, Løkken N, Vissing J
Muscle & nerve 2017; (56(4)):696-699 doi:10.1002/mus.25549.
PMID: 28039888 - 18
Myotonic disorders and pregnancy.
Morton A
Obstetric medicine 2020; (13(1)):14-19 doi:10.1177/1753495X18824238.
PMID: 32284727
This page is for informational purposes only and does not constitute medical advice. It explains Thomsen and Becker disease, but your neuromuscular specialist should interpret your genetic results and treatment options.